Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 5/20 | 0.48 |
| ▸ | SLC9A1 | P19634 | 5/20 | 0.45 |
| ▸ | HTR2C | P28335 | 2/20 | 0.43 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.42 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.41 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.41 |
| ▸ | RBP4 | P02753 | 2/20 | 0.40 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
| ▸ | SLC9A2 | Q9UBY0 | 1/20 | 0.39 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.39 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.39 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.38 |
| ▸ | KIF11 | P52732 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22084408 | 0.93 | SLC9A1 (0.43) | NOTUMSLC9A1HTR2CCHRNB2CHRNA4 | |
| SCHEMBL3856782 | 0.91 | SLC9A1 (0.43) | NOTUMSLC9A1HTR2CCHRNB2CHRNA4 | |
| SCHEMBL25385012 | 0.88 | NOTUM (0.43) | NOTUMSLC9A1HTR2CCHRNB2CHRNA4 | |
| SCHEMBL29566996 | 0.85 | CYP3A4 (0.51) | SLC9A1RBP4ADRA1DHTR2ASLC6A3 | |
| SCHEMBL24310295 | 0.85 | CYP3A4 (0.51) | SLC9A1RBP4ADRA1DHTR2ASLC6A3 | |
| SCHEMBL31316981 | 0.79 | CFTR (0.40) | NOTUMSLC9A1CHRNB2CHRNA4PDE3B | |
| SCHEMBL3655800 | 0.77 | TRPV1 (0.45) | SLC9A1CHRNB2CHRNA4 | |
| SCHEMBL16957247 | 0.77 | NOTUM (0.54) | NOTUMSLC9A1HTR2CCHRNB2CHRNA4 | |
| SCHEMBL14592943 | 0.77 | TSHR (0.53) | NOTUMSLC9A1HTR2CCHRNB2CHRNA4 | |
| SCHEMBL16957244 | 0.77 | NOTUM (0.51) | NOTUMSLC9A1HTR2CPDE3BPDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102137851-B | Compound as vanilloid receptor antagonist, isomer thereof or pharmaceutically acceptable salt thereof, and pharmaceutical composition comprising same | AMOREPACIFIC CORP | 2014-08-27 | — | — | CN | disclosed |
| EP-2307394-B1 | SULPHONAMIDES AS VANILLOID RECEPTOR ANTAGONIST | AMOREPACIFIC CORP (KR) | 2012-09-26 | — | — | EP | disclosed |
| CN-102137851-A | Novel compounds as vanilloid receptor antagonists, isomers thereof or pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the same | AMOREPACIFIC CORP | 2011-07-27 | — | — | CN | disclosed |
| US-20110152318-A1 | NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | AMOREPACIFIC CORPORATION (KR) | 2011-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152318-A1 | NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | TRPV1, TRPA1, TRPV2 | NOTUM 3391/4885SLC9A1 183/4885HTR2C 274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.